S S M Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.60 M
as on 24-06-2024
- Paid Up Capital ₹ 1.51 M
as on 24-06-2024
- Company Age 42 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.60 M
as on 24-06-2024
- Revenue -20.75%
(FY 2021)
- Profit -8723.23%
(FY 2021)
- Ebitda -135.88%
(FY 2021)
- Net Worth -9.24%
(FY 2021)
- Total Assets -7.81%
(FY 2021)
About S S M Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.60 M and a paid-up capital of Rs 1.51 M.
The company has closed loans amounting to ₹1.60 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Nitesh Sethia, Niranjan Sethia, and Urmila Sethia serve as directors at the Company.
- CIN/LLPIN
U24232RJ1982PTC002502
- Company No.
002502
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jun 1982
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does S S M Pharmaceuticals Private Limited offer?
S S M Pharmaceuticals Private Limited offers a wide range of products and services, including Cough Syrup.
Who are the key members and board of directors at S S M Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitesh Sethia  | Director | 20-Oct-2007 | Current |
| Niranjan Sethia | Director | 28-Sep-1998 | Current |
| Urmila Sethia | Director | 02-Jul-2001 | Current |
Financial Performance and Corporate Structure Insights of S S M Pharmaceuticals.
S S M Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 20.75% decrease. The company also saw a substantial fall in profitability, with a 8723.23% decrease in profit. The company's net worth dipped by a decrease of 9.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of S S M Pharmaceuticals?
In 2019, S S M Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jai Uttam Buildhome Private LimitedActive 20 years 8 monthsNitesh Sethia and Niranjan Sethia are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 01 Sep 2003 | ₹1.60 M | Satisfied |
How Many Employees Work at S S M Pharmaceuticals?
S S M Pharmaceuticals has a workforce of 4 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S S M Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S S M Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
